Cubist Pharms Llc Drug Patent Portfolio
Cubist Pharms Llc owns 5 orange book drugs protected by 40 US patents with Cubicin Rf having the least patent protection, holding only 1 patent. And Zerbaxa with maximum patent protection, holding 14 patents. Given below is the list of Cubist Pharms Llc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10125149 | Synthesis of cephalosporin compounds | 14 Aug, 2035 | Active |
| US9808530 | Composition of tiacumicin compounds | 28 Nov, 2034 | Active |
| US10376496 | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function | 09 Sep, 2034 | Active |
| US10933053 | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function | 09 Sep, 2034 | Active |
| US9808530 | Composition of tiacumicin compounds | 28 May, 2034 | Active |
| US8906898 | Solid forms of ceftolozane | 28 May, 2034 | Active |
| US10420841 | Ceftolozane antibiotic compositions | 14 Mar, 2034 | Active |
| US11278622 | Ceftolozane antibiotic compositions | 14 Mar, 2034 | Active |
| US8968753 | Ceftolozane-tazobactam pharmaceutical compositions | 14 Mar, 2034 | Active |
| US9320740 | Ceftolozane-tazobactam pharmaceutical compositions | 14 Mar, 2034 | Active |
| US9872906 | Ceftolozane antibiotic compositions | 14 Mar, 2034 | Active |
| US8476425 | Tazobactam arginine compositions | 27 Sep, 2032 | Active |
| US8685957 | Tazobactam arginine compositions | 27 Sep, 2032 | Active |
| US10028963 | Methods for treating intrapulmonary infections | 07 Sep, 2032 | Active |
| US9724353 | Methods for treating intrapulmonary infections | 07 Sep, 2032 | Active |
| US8426389 | Crystalline form of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate | 31 Dec, 2030 | Active |
| US9138456 | Lipopeptide compositions and related methods | 23 Nov, 2030 | Active |
| US10065947 | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate | 03 Feb, 2030 | Active |
| US10442829 | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate | 03 Feb, 2030 | Active |
| US9624250 | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate | 03 Feb, 2030 | Active |
| US9988406 | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate | 03 Feb, 2030 | Active |
| US8003673 | Daptomycin for the treatment of biofilm and catheter salvage | 04 Sep, 2028 | Active |
| US7816379 | Oxazolidinone derivatives | 20 Jun, 2028 | Active |
| US7129232 | Cephem compounds | 15 May, 2028 | Active |
| US8420676 | Oxazolidinone derivatives | 23 Feb, 2028 | Active |
| US7378508 | Polymorphic crystalline forms of tiacumicin B | 31 Jan, 2028 | Active |
| US7863249 | Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof | 31 Jan, 2028 | Active |
| US8859510 | Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof | 31 Jan, 2028 | Active |
| US7906489 | 18-membered macrocycles and analogs thereof | 04 Sep, 2027 | Active |
| US7378508 | Polymorphic crystalline forms of tiacumicin B | 31 Jul, 2027 | Active |
| US7863249 | Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof | 31 Jul, 2027 | Active |
| US8859510 | Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof | 31 Jul, 2027 | Active |
| US7906489 | 18-membered macrocycles and analogs thereof | 04 Mar, 2027 | Active |
| US8586551 | 18-membered macrocycles and analogs thereof | 15 Jan, 2024 | Expired |
| US8586551 | 18-membered macrocycles and analogs thereof | 23 Jul, 2023 | Expired |
| US8058238 | High purity lipopeptides | 28 Nov, 2020 | Expired |
| US8129342 | High purity lipopeptides | 28 Nov, 2020 | Expired |
| US6468967 | Methods for administration of antibiotics | 24 Sep, 2019 | Expired |
| US6852689 | Methods for administration of antibiotics | 24 Sep, 2019 | Expired |
| USRE39071 | Anhydro-and isomer-a-21978c cyclic peptides | 15 Jun, 2016 | Expired |
Latest Legal Activities on Cubist Pharms Llc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Cubist Pharms Llc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Expire Patent
Critical
| 08 Apr, 2024 | US8129342 (Litigated) |
|
Expire Patent
Critical
| 18 Dec, 2023 | US8058238 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 23 Oct, 2023 | US8129342 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 03 Jul, 2023 | US8058238 (Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 09 Mar, 2023 | US10442829 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 08 Feb, 2023 | US9138456 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 08 Feb, 2023 | US10420841 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 08 Feb, 2023 | US9138456 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 11 Jan, 2023 | US10376496 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 11 Jan, 2023 | US8003673 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 10 Aug, 2022 | US7906489 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 08 Jun, 2022 | US7863249 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 May, 2022 | US8906898 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 12 Apr, 2022 | US10125149 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 22 Mar, 2022 | US11278622 |
Cubist Pharms Llc's Drug Patent Litigations
Cubist Pharms Llc's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 23, 2014, against patent number US8129342. The petitioner Agila Specialities Inc., challenged the validity of this patent, with Cubist Pharmaceuticals, Inc. as the respondent. Click below to track the latest information on how companies are challenging Cubist Pharms Llc's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US9138456 | November, 2019 |
Terminated-Denied
(29 May, 2020)
| Cubist Pharmaceuticals LLC | Amneal Pharmaceuticals LLC |
| US8058238 | July, 2015 |
Terminated-Settled
(14 Jun, 2016)
| Cubist Pharmaceuticals LLC | Fresenius Kabi USA LLC |
| US8129342 | July, 2015 |
Terminated-Settled
(14 Jun, 2016)
| Cubist Pharmaceuticals LLC | Fresenius Kabi USA LLC |
| US6468967 | November, 2014 |
FWD Entered
(12 May, 2016)
| Cubist Pharmaceuticals LLC | Fresenius-Kabi USA LLC |
| US6852689 | November, 2014 |
FWD Entered
(12 May, 2016)
| Cubist Pharmaceuticals LLC | Fresenius-Kabi USA LLC |
| US8058238 | July, 2015 |
Terminated-Denied
(28 Jan, 2016)
| Cubist Pharmaceuticals LLC | Fresenius Kabi USA LLC |
| US6468967 | October, 2014 |
Terminated-Denied
(28 Apr, 2015)
| Cubist Pharmaceuticals, Inc. | Agila Specialties Inc. |
| US6852689 | October, 2014 |
Terminated-Denied
(28 Apr, 2015)
| Cubist Pharmaceuticals Incorporated | Agila Specialties Inc. |
| US8058238 | October, 2014 |
Terminated-Denied
(28 Apr, 2015)
| Cubist Pharmaceuticals, Inc. | Agila Specialities Inc. |
| US8058238 | October, 2014 |
Terminated-Denied
(28 Apr, 2015)
| Cubist Pharmaceuticals, Inc. | Agila Specialties Inc. |
| US8129342 | October, 2014 |
Terminated-Denied
(28 Apr, 2015)
| Cubist Pharmaceuticals, Inc. | Agila Specialities Inc. |
Cubist Pharms Llc Drug Patents' Oppositions Filed in EPO
Cubist Pharms Llc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 10, 2019, by Hgf Limited. This opposition was filed on patent number EP10832379A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP14842042A | Dec, 2020 | Lederer & Keller Patentanwälte Partnerschaft mbB | Opposition rejected |
| EP10832379A | Apr, 2019 | Pajaro Limited | Granted and Under Opposition |
| EP10832379A | Apr, 2019 | HGF Limited | Granted and Under Opposition |
Cubist Pharms Llc's Family Patents
Cubist Pharms Llc Drug List
Given below is the complete list of Cubist Pharms Llc's drugs and the patents protecting them.
1. Cubicin
Cubicin is protected by 7 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9138456 | Lipopeptide compositions and related methods |
23 Nov, 2030
(5 years from now)
| Active |
| US8003673 | Daptomycin for the treatment of biofilm and catheter salvage |
04 Sep, 2028
(3 years from now)
| Active |
| US8058238 | High purity lipopeptides |
28 Nov, 2020
(4 years ago)
| Expired |
| US8129342 | High purity lipopeptides |
28 Nov, 2020
(4 years ago)
| Expired |
| US6468967 | Methods for administration of antibiotics |
24 Sep, 2019
(5 years ago)
| Expired |
| US6852689 | Methods for administration of antibiotics |
24 Sep, 2019
(5 years ago)
| Expired |
| USRE39071 | Anhydro-and isomer-a-21978c cyclic peptides |
15 Jun, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cubicin's drug page
2. Cubicin Rf
Cubicin Rf is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9138456 | Lipopeptide compositions and related methods |
23 Nov, 2030
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cubicin Rf's drug page
3. Dificid
Dificid is protected by 13 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9808530
(Pediatric)
| Composition of tiacumicin compounds |
28 Nov, 2034
(9 years from now)
| Active |
| US9808530 | Composition of tiacumicin compounds |
28 May, 2034
(9 years from now)
| Active |
| US7378508
(Pediatric)
| Polymorphic crystalline forms of tiacumicin B |
31 Jan, 2028
(2 years from now)
| Active |
| US7863249
(Pediatric)
| Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
31 Jan, 2028
(2 years from now)
| Active |
| US8859510
(Pediatric)
| Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
31 Jan, 2028
(2 years from now)
| Active |
| US7906489
(Pediatric)
| 18-membered macrocycles and analogs thereof |
04 Sep, 2027
(2 years from now)
| Active |
| US7378508 | Polymorphic crystalline forms of tiacumicin B |
31 Jul, 2027
(2 years from now)
| Active |
| US7863249 | Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
31 Jul, 2027
(2 years from now)
| Active |
| US8859510 | Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
31 Jul, 2027
(2 years from now)
| Active |
| US7906489 | 18-membered macrocycles and analogs thereof |
04 Mar, 2027
(1 year, 9 months from now)
| Active |
| US8586551
(Pediatric)
| 18-membered macrocycles and analogs thereof |
15 Jan, 2024
(1 year, 3 months ago)
| Expired |
| US8586551 | 18-membered macrocycles and analogs thereof |
23 Jul, 2023
(1 year, 9 months ago)
| Expired |
| US8586551 | 18-membered macrocycles and analogs thereof |
15 Jul, 2023
(1 year, 9 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dificid's drug page
4. Sivextro
Sivextro is protected by 7 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8426389 | Crystalline form of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
31 Dec, 2030
(5 years from now)
| Active |
| US10065947 | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
03 Feb, 2030
(4 years from now)
| Active |
| US10442829 | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
03 Feb, 2030
(4 years from now)
| Active |
| US9624250 | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
03 Feb, 2030
(4 years from now)
| Active |
| US9988406 | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
03 Feb, 2030
(4 years from now)
| Active |
| US7816379 | Oxazolidinone derivatives |
20 Jun, 2028
(3 years from now)
| Active |
| US8420676 | Oxazolidinone derivatives |
23 Feb, 2028
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sivextro's drug page
5. Zerbaxa
Zerbaxa is protected by 14 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10125149 | Synthesis of cephalosporin compounds |
14 Aug, 2035
(10 years from now)
| Active |
| US10376496 | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
09 Sep, 2034
(9 years from now)
| Active |
| US10933053 | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
09 Sep, 2034
(9 years from now)
| Active |
| US8906898 | Solid forms of ceftolozane |
28 May, 2034
(9 years from now)
| Active |
| US10420841 | Ceftolozane antibiotic compositions |
14 Mar, 2034
(8 years from now)
| Active |
| US11278622 | Ceftolozane antibiotic compositions |
14 Mar, 2034
(8 years from now)
| Active |
| US8968753 | Ceftolozane-tazobactam pharmaceutical compositions |
14 Mar, 2034
(8 years from now)
| Active |
| US9320740 | Ceftolozane-tazobactam pharmaceutical compositions |
14 Mar, 2034
(8 years from now)
| Active |
| US9872906 | Ceftolozane antibiotic compositions |
14 Mar, 2034
(8 years from now)
| Active |
| US8476425 | Tazobactam arginine compositions |
27 Sep, 2032
(7 years from now)
| Active |
| US8685957 | Tazobactam arginine compositions |
27 Sep, 2032
(7 years from now)
| Active |
| US10028963 | Methods for treating intrapulmonary infections |
07 Sep, 2032
(7 years from now)
| Active |
| US9724353 | Methods for treating intrapulmonary infections |
07 Sep, 2032
(7 years from now)
| Active |
| US7129232 | Cephem compounds |
15 May, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zerbaxa's drug page